Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Glimepiride on Inflammatory Cytokines in T2DM
NCT02964572Completed
- Sponsor
- Yonsei University
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yonsei University. Primary endpoint: Secretion of IL-1 beta from peripheral blood mononuclear cells at Day 60. Started Nov 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02964572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964572.